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Introductory Chapter:  




Urticaria is one of the most common pruritic skin diseases which is characterized  
by the occurence of recurrent erythematous and edematous wheals with or 
 without angioedema. These wheals appear at different body areas and dissapear 
within 24 hours while new lesions may occur. The disease may be characterized 
as idiopathic or inducible depending on the potential trigger factors and acute 
or chronic depending on the duration of the symptoms for less or more than 
6 weeks [1].
The lifetime prevalence of chronic urticaria is about 10–20%. Urticaria can 
occur at any age but the chronic form is more common in adults, especially during 
the third and fourth decade of life. The disease can affect both women and men but 
there is evidence of a female predominance [2].
The pathomechanismus of urticaria is based in the release of various mediators 
due to degranulation of activated subepidermal mast cells. Released histamine 
causes local vasodilation and increased capillary permeability, resulting in intracu-
taneous (wheal) or subcutaneous (angioedema) edema. Furthermore, activation of 
sensory nerves leads to pruritus and reflex erythema. The mast cell degranulation 
may be caused by different mechanisms such as direct activation or IgE-mediated 
allergic activation and results to the release of mediators such as histamin, which is 
responsible for the pruritus which ist he main symptom in urticaria. Beside pru-
ritus, these vasoactive mediators are responsible for vasodilation and subsequent 
erythema and edema [3].
Chronic urticaria can be characterized as spontaneous when no trigger factors 
are known or as inducible when the appearance of wheals is caused by specific trig-
ger factors. There are many triggering factors for chronic urticaria but determining 
a specific cause is not always possible.
The most common ones include viral, bacterial or parasitic infections, specific 
drugs (e.g. nonsteroidal anti-inflammatory drugs and antibiotics), foods, physical 
factors (such as pressure, exposure to light, heat or cold, vibration, exercise and 
increased body temperature) and emotional stress [4]. Furthermore, autoimmune 
and systemic diseases and also malignancies can be the underlying factor of urti-
caria and should be taken into consideration in the diagnosis of the disease. Some of 
the most common systemic disorders involved in urticaria are lupus erythematosus, 
cutaneous vasculitis, Sjögren‘s syndrome, autoimmune thyroid disease, rheumatoid 
arthritis and diabetes mellitus [5]. All these factors and conditions will be thor-
oughly disscussed in this book giving the reader a complete guideline to diagnose 
and define different types of urticaria.
Urticaria - Diagnosis and Management
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Diagnosis of urticaria is mainly based on anamnesis and clinical examination of 
the patient. However, due to the transient character of the skin manifestations this 
may be difficult at the time of examination. Sometimes, photos or re-examination 
of he patient when the lesions are present are necessary and helpful for the clinician 
in order to make the diagnosis. Thorough clinical history and a potential association 
with angioedema and/or anaphylaxis should always be asked.
Clinical manifestation of urticaria is characteristic with circumscribed wheals 
in any region of the body which commonly persist no longer than 24 hours and 
reappear at different body areas. Pruritus is the major symptom patients claim for 
which affects their daily activities and quality of life. If the lesions persist longer 
than 24 hours, appear in combination with skin manifestations such as petechia or 
hyperpigmentation, or are accombanied by systemic symptoms such as fever and 
arthralgia, more severe conditions such as urticaria vasculitis have to be excluded 
with a skin biopsy.
Skin biopsy can be helpful if systemic diseases such are vasculitis or mastocyto-
sis are suspected. Histopathological findings of urticaria include interstitial edema 
and perivascular mixed cellular infiltrate. T-lymphocytes are predominant in this 
infiltrate but also eosinophils, neutrophils, and basophils may also be present.
Once the diagnosis is confirmed, it is important to find out potential trigger 
factors, if possible. Detailed anamnesis is important to determine any triggering 
infection, drugs or physical factor. Challenge tests may be then individually per-
formed to confirm the different types of inducible urticaria.
Skin tests such as an autologous serum test may be useful in order to exclude the 
autoimmune type of urticaria. During this test patient’s own serum is intradermally 
injected on the forearm oft he patient and is positiv if an urticarial reaction appears 
within 30 min.
Laboratory tests are in general not indicated for patients with acute urticaria 
unless they have signs and symptoms suggesting an underlying systemic disease. 
In cases of chronic urticaria besides a standard laboratory examination additional 
tests such as antinuclear antibody, autoantibodies, rheumatoid factor, complement 
C3 and C4 levels, thyroid parameters, Helicobacter pylori antigen, hepatitis and 
parasite examination are essential in ordert to exclude an infection or an underlying 
autoimmune disease [1, 6].
The severity of the disease can be individual evaluated using some scoring 
systems used for this purpose, one of which is the urticaria activity score (UAS). 
This is a widely used scoring system questioning the intensity of pruritus and the 
number of wheals in a day and can be further used to also evaluate the effectivity of 
the therapy in later stages [7].
If an association with trigger factors has been established, the prevention of trig-
ger is the first step of treatment. The next step includes drugs in order to control the 
symptoms with minimal side effects. Second-generation H1 antihistamines, such 
as cetirizine and loratadine, are used as first-line treatment options. These newer, 
antihistamines ahave a non-sedative character compared to the first-generation 
ones such as hydroxyzine and diphenhydramine and thus are mopstly preffered. 
In severe cases, a dose increasement up to fourfold of standard therapeutic doses is 
recommended by the latest guidelines. In certain cases, H2 antihistamines may be 
used in combination with H1 antihistamines.
Glucocortikosteroids may be used for a short period of time and at the lowest 
dose in addition to antihistamines for acute urticarial attacks, particularly when 
accompanied by angioedema. Long-term use of systemic glucocorticoids is not 
recommended because of potential adverse effects.
In chronic cases where the symptoms persist despite high-dose antihis-
tamines. Antileukotrienes, such as montelukast, zafirlukast as well as the 
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5-lipoxygenase-inhibitor zileuton are added to antihistamines as second-line 
treatment options. Furthermore, immunosuppressive agents, such as cyclosporine, 
are effective in the treatment of chronic urticaria but the clinicians and the patients 
should be aware of the potential side effects. Other less used drugs such as dapsone, 
hydroxychloroquine, sulfasalazine, azathioprin and mycophenolate have also been 
used in the treatment of urticaria [1].
Biologic agents such as omalizumab has recently been added in the treatment of 
chronic urticaria in adults and adolescents that continue to be symptomatic despite 
the use H1 antihistamines. It is an anti-IgE monoclonal antibody which has a good 
efficacy and safety profile in most oft he patients and can be easily applied with 
monthly subcutaneous injections [8]. Further research is being made and current 
data indicate ligelizumab, a next-generation anti-IgE antibody as a potential valid 
alternative for patients with chronic urticaria unresponsive to omalizumab. Other 
IgE-antibodies and diverse anti-IL factors are also being studied and may show a 
potential role in the treatment of urticaria [9].
2. Conclusion
In view of the pathomechanism and the different forms of urticaria, the treat-
ment of the disease is a real concern over the opportunities and therapeutic options 
already available and over all other strategies under development and trials. In 
this context, it is believed that we will be able personalize the management plan of 
urticaria in the future and we are close the identification of specific biomarkers for 
different types of the disease which could also be used as monitoring markers.
This book presents the most current knowledge in the diagnosis and manage-
ment of urticaria. It also examines the scientific aspect of currently available treat-
ments as well as potential new options for managing severe forms of the disease. 
The different chapters, written by expert authors all over the world, address some 
of the most important aspects in the diagnosis and management of urticaria.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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